Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments

J Neuroimmunol. 2011 Apr;233(1-2):168-74. doi: 10.1016/j.jneuroim.2010.10.038. Epub 2010 Nov 27.

Abstract

Using retrospectively collected outcome data for treatment naïve subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN β) (n=424), we replicated the lack of a significant difference in efficacy between these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Drug Resistance / genetics
  • Drug Resistance / immunology
  • Female
  • Glatiramer Acetate
  • HLA-DR Antigens / genetics*
  • HLA-DRB1 Chains
  • Humans
  • Interferon Regulatory Factors / genetics
  • Interferon-beta / pharmacology
  • Interferon-beta / therapeutic use
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / genetics
  • Multiple Sclerosis / immunology*
  • Peptides / pharmacology
  • Peptides / therapeutic use
  • Retrospective Studies

Substances

  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • HLA-DRB1*15:01 antigen
  • Interferon Regulatory Factors
  • Peptides
  • interferon regulatory factor-8
  • Glatiramer Acetate
  • Interferon-beta